Back
Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial.
Journal article

Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: A randomized controlled trial.

  • Elmorshedy H Department of Tropical Health, High Institute of Public Health, University Of Alexandria, Egypt. Electronic address: elmorshedyh@hotmail.com.
  • Tanner M The Swiss Tropical and Public Health Institute (Swiss TPH), Switzerland; University of Basel, Basel, Switzerland. Electronic address: marcel.tanner@unibas.ch.
  • Bergquist RN University of Basel, Basel, Switzerland; Ingerod, Brastad, Sweden. Electronic address: robert.bergquist@outlook.com.
  • Sharaf S Parasitology Department, National Liver Institute, Menoufeya University, Menoufeya, Egypt. Electronic address: Soraya_sharaf@yahoo.com.
  • Barakat R Department of Tropical Health, High Institute of Public Health, University Of Alexandria, Egypt.
Show more…
  • 2016-02-28
Published in:
  • Acta tropica. - 2016
Artemether
Egypt
Praziquantel
Prophylaxis
Randomized control trial
Schistosoma mansoni
Animals
Artemether
Artemisinins
Child
Child, Preschool
Double-Blind Method
Egypt
Female
Humans
Incidence
Male
Praziquantel
Prevalence
Schistosoma mansoni
Schistosomiasis mansoni
Schistosomicides
Schools
English A double-blind, randomized controlled trial was conducted in an endemic focus for Schistosoma mansoni in Kafr El-Sheikh Governorate, Northern Nile Delta, Egypt, to evaluate the prophylactic effect of artemether (ART) given in conjunction with praziquantel (PZQ). The study encompassed 913 primary school children randomly assigned to two treatment groups PZQ/ART and PZQ/ART-placebo. At baseline, both groups received 40 mg/kg body weight of PZQ twice four weeks apart, after which one group received 6 mg/kg body weight of ART every 3 weeks in 5 cycles during the transmission season and the other group received ART-placebo. At the end of the study, prevalence of infection among the PZQ/ART was approximately half that of the PZQ/ART-placebo group, i.e. 6.7% versus 11.6%, and incidence of new infections for the PZQ/ART was 2.7% versus 6.5% for the PZQ/ART-placebo. In conclusion, PZQ/ART combined therapy might be considered as an adjunct measure against human schistosomiasis, by specifically reducing transmission and therefore contribute to disease elimination.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/270285
Statistics
Document views: 20 File downloads: